Searchable abstracts of presentations at key conferences in endocrinology

ea0029p48 | Adrenal cortex | ICEECE2012

MicroRNA profiling of benign and malignant adrenocortical tumors reveals potential biomarkers of recurrence

Chabre O. , Assie G. , Libe R. , Bertherat J. , Feige J. , Cherradi N.

Objective: To identify miRNAs predictors of poor prognosis in adrenocortical cancer.Methods: Using microarrays, we evaluated the expression of 728 human miRNAs in six adenomas (ACAs) and twelve carcinomas (ACCs). The ACC group was composed of two subgroups A and B consisting of six recurrent (subgroup A) and six non-recurrent tumors (subgroup B). These two distinct subgroups have been characterized recently (de Reynies et al, 2009) on the basis of distin...

ea0029p29 | Adrenal cortex | ICEECE2012

The ACTH-independent macronodular adrenal hyperplasia gene hunt: from candidate genes to a pangenomic strategy

Assie G. , Libe R. , Guimier A. , Espiard S. , Rene-Corail F. , Perlemoine K. , Letourneur F. , Bertagna X. , Groussin L. , Bertherat J.

ACTH-independent macronodular hyperplasia (AIMAH) affects both adrenals, and familial forms are reported, suggesting a genetic origin. Rare mutations have been reported in several genes, including Gs alpha (GNAS), Phosphodiesterase 11A (PDE11A), Fumarate Hydratase (FH), and the Glucocorticoids receptor (GR).Objective: To assess the prevalence known genes mutations, and identify new candidate genes in AIMAH.Design and methods: Germl...

ea0029oc13.4 | Adrenal Basic | ICEECE2012

A genome-wide methylation study of adrenocortical tumors shows specific alterations linked to gene expression, revealing new aspects of the molecular classification of adrenal carcinomas

Assie G. , Barreau O. , Wilmot-Roussel H. , Ragazzon B. , Baudry C. , Perlemoine K. , Rene-Corail F. , Dousset B. , Bertagna X. , Tissier F. , De Reynies A. , Bertherat J.

Introduction: DNA methylation is a mechanism for gene expression dysregulation in cancer. Little is known about methylation in adrenocortical tumors (ACT). Previous transcriptome studies proposed an original classification of ACT, first discriminating carcinomas from adenomas, then separating the carcinomas in two groups with different prognosis (C1A and C1B), the poor outcome group (C1A) being divided in three subgroups: p53 inactivation sub-group (C1Ap53), β-catenin act...